We demonstrated that Batf3+ DCs are also critical for the recruitment of CD8+ T cells in our melanoma model following treatment with T-VEC and trametinib, and observed an increase in CXCL9 expression

We demonstrated that Batf3+ DCs are also critical for the recruitment of CD8+ T cells in our melanoma model following treatment with T-VEC and trametinib, and observed an increase in CXCL9 expression

We demonstrated that Batf3+ DCs are also critical for the recruitment of CD8+ T cells in our melanoma model following treatment with T-VEC and trametinib, and observed an increase in CXCL9 expression. malignancy but advances over the past decade have resulted in multiple new therapeutic